CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Pemetrexed and Gemcitabine plus Bevacizumabdrug
Likely dose
Pemetrexed and Gemcitabine plus Bevacizumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00517595
NCT00517595Phase 2Completed
CompareCT.gov

A Phase II Study of Pemetrexed and Gemcitabine Plus Bevacizumab as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV Non-Small Cell Lung Cancer

Accelerated Community Oncology Research Network·interventional·Posted Aug 17, 2007·Updated Mar 12, 2012

In Brief

A Phase 2 clinical trial evaluating Pemetrexed and Gemcitabine plus Bevacizumab for Non-Small Cell Lung Cancer. Completed, enrolled 48 participants across 10 sites.

Detailed Summary

The primary objective is to determine the progression free survival with pemetrexed, and gemcitabine plus bevacizumab as first-line chemotherapy in elderly patients with Stage IIIB/IV non-small cell lung cancer (NSCLC). The secondary objectives are to determine the overall response rate; overall survival; chemotherapy induced toxicity profile of this combination; time to progression; and patient reported symptom burden.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsEli Lilly and Company, Genentech, Inc.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 17, 2007
Enrollment StartAug 1, 2007
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.9 years ago

Interventions

Pemetrexed and Gemcitabine plus Bevacizumabdrug

Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m\^2 and gemcitabine 1500 mg/m\^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.